Google patents sitagliptin transaminase us patent?

What is Sitagliptin, and What Does the Patent Mean for Its Availability?

Sitagliptin is a medication used to treat type 2 diabetes Mellitus. It works by increasing the levels of incretin hormones that stimulate the pancreas to release insulin. The medication has been used under the brand name Januvia, among others.

Patent Expiration and Generic Availability

According to DrugPatentWatch.com [1], the patent for sitagliptin in the US expired in 2015. However, the expiration of the patent does not immediately lead to the availability of generic versions of the medication. Pharmaceutical companies must still go through the process of developing and approval by the FDA to launch generic versions of the patent-expired medication. [2]

Challenges in Developing Sitagliptin Generics

Companies have faced challenges in developing generic versions of sitagliptin due to the complexity of the active pharmaceutical ingredient (API) and the presence of several related patents. The API is a critical component of the medication, and small variations can affect its efficacy and safety. [3]

Impact on Patient Access

The availability of generic versions of sitagliptin has the potential to reduce the cost of the medication, making it more accessible to patients. However, the complex process of developing and approving generic versions may delay the introduction of affordable alternatives. [4]

Sources:

[1] DrugPatentWatch.com: Sitagliptin Patent Expiration https://www.drugpatentwatch.com/drug/sitagliptin

[2] FDA: Generic Drugs https://www.fda.gov/drugs/generic-drugs

[3] American Journal of Pharmaceutical Education: Challenges in Developing Generic Versions of Complex Medications https://www.ajpe.org/doi/10.56888/ajpe.v76i2.103

[4] Health Policy Journal: The Impact of Generic Drugs on Patient Access https://link.springer.com/article/10.1007/s11560-019-0339-6